Evolving Refractory Major Depressive Disorder Diagnostic and Treatment Paradigms: Toward Closed-Loop Therapeutics

@article{Ward2010EvolvingRM,
  title={Evolving Refractory Major Depressive Disorder Diagnostic and Treatment Paradigms: Toward Closed-Loop Therapeutics},
  author={Matthew P. Ward and Pedro P. Irazoqui},
  journal={Frontiers in Neuroengineering},
  year={2010},
  volume={3}
}
  • M. Ward, P. Irazoqui
  • Published 1 March 2010
  • Psychology, Medicine
  • Frontiers in Neuroengineering
Current antidepressant therapies do not effectively control or cure depressive symptoms. Pharmaceutical therapies altogether fail to address an estimated 4 million Americans who suffer from a recurrent and severe treatment-resistant form of depression known as refractory major depressive disorder. Subjective diagnostic schemes, differing manifestations of the disorder, and antidepressant treatments with limited theoretical bases each contribute to the general lack of therapeutic efficacy and… 

Tables from this paper

Treatment-resistant depression: therapeutic trends, challenges, and future directions

  • K. S. Al-Harbi
  • Psychology, Medicine
    Patient preference and adherence
  • 2012
Treatment-resistant depression continues to challenge mental health care providers, and further relevant research involving newer drugs is warranted to improve the quality of life of patients with the disorder.

Intensive HF-rTMS treatment in refractory medication-resistant unipolar depressed patients.

Atypical antipsychotics in major depressive disorder

The present chapter aims at reviewing literature and data evaluating the efficacy and effectiveness of prescribing atypical antipsychotic as add-on therapy in MDD.

Neuromodulation therapies and treatment-resistant depression

NTs are promising in patients withTRD, as the majority of them show good clinical response measured by standardized depression scales, and need further technological refinements and optimization together with continuing well-designed studies that recruit larger numbers of participants with TRD.

Biomarkers for Deep Brain Stimulation in Animal Models of Depression.

DBS is a promising therapeutic modality for treatment-resistant depression and electrophysiological and biochemical markers appear to offer the greatest potential as biomarkers for depression, but additional preclinical and clinical studies with a focus on identifying reliable, safe, and effective biomarkers are warranted.

Vitamin D: An Anti-Inflammatory Treatment Option for Depression?

Principal approaches to its management include novel antidepressants, adjunct second generation antipsychotic agents and mood stabilizers, evidence-based psychotherapies, and complementary and alternative therapies.

New neuromodulation techniques for treatment resistant depression

An overview of current progress in the technological advances in neuromodulation and neurostimulation treatments for treatment-resistant depression shows there is a critical need for new therapies for treatment resistant depression.

References

SHOWING 1-10 OF 167 REFERENCES

Neurostimulatory therapeutics in management of treatment-resistant depression with focus on deep brain stimulation.

Although deep brain stimulation is the most invasive of the neurostimulatory treatments developed to date, it may hold significant promise in alleviating symptoms and improving the quality of life for patients with the most severe and disabling mood disorders.

VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms

Evidence from neuroimaging and other studies suggests that VNS therapy acts via innervation of the nucleus tractus solitarius, with secondary projections to limbic and cortical structures that are involved in mood regulation, including brainstem regions that contain serotonergic and noradrenergic regions that project to the forebrain.

Treatment-resistant depression.

Clinical studies investigating the predictors of resistance following the failure of 2 or more antidepressant trials should be pursued, and further controlled clinical trials are essential to identify the most effective treatment strategies.

Deep Brain Stimulation for Treatment-Resistant

It is suggested that disrupting focal pathological activity in limbic-cortical circuits using electrical stimulation of the subgenual cingulate white matter can effectively reverse symptoms in otherwise treatment-resistant depression.

A Patient with a Resistant Major Depression Disorder Treated with Deep Brain Stimulation in the Inferior Thalamic Peduncle

Promising results of electrical stimulation of the inferior thalamic peduncle are presented to treat recurrent unipolar depression in a patient with resistant major depression disorder and borderline personality disorder who responded poorly to treatment.

Diagnosis and definition of treatment-resistant depression

  • M. Fava
  • Psychology, Medicine
    Biological Psychiatry
  • 2003

Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy.

Brain changes underlying response to CBT were examined using resting-state fluorine-18-labeled deoxyglucose positron emission tomography to examine changes associated with cognitive behavior therapy (CBT).

Carbamazepine in manic-depressive illness: a new treatment.

The authors evaluated carbamazepine (Tegretol), a drug of choice for treatment of temporal lobe epilepsy, in a double-blind placebo-controlled trial in patients with manic-depressive illness. Seven
...